# A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)

> **NCT00924781** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 39 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
- **DRUG:** MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
- **DRUG:** MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline

## Key facts

- **NCT ID:** NCT00924781
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2010-04
- **Final completion:** 2010-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924781, "A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00924781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*